Dr. Pemmaraju on the Ongoing Trial of Tagraxofusp in Myelofibrosis
August 30th 2019Naveen Pemmaraju, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the ongoing phase I/II trial of tagraxofusp (SL-401; Elzonris) in patients with intermediate- or high-risk relapsed/refractory myelofibrosis.
Read More
Dr. Pemmaraju on the Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasms
August 10th 2018Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the trial of SL-401 in blastic plasmacytoid dendritic cell neoplasms.
Read More
Dr. Pemmaraju on SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasms
July 24th 2018Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasms.
Read More
Dr. Pemmaraju on Clinical Trial Results of LCL161 in High-Risk Myelofibrosis
December 13th 2017Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the clinical trial results for LCL161 in patients with intermediate or high-risk myelofibrosis.
Read More
PSMA-PET Plus Multi-Parametric MRI Aids Detection of Clinically Significant Prostate Cancer
Enzalutamide Improves Undetectable PSA Rates Alone and With Leuprolide in Nonmetastatic CSPC
Dr Shore on the Importance of a Multidisciplinary Team in Urologic Oncology
Apalutamide/ADT Demonstrates 100% Biochemical RFS Rate in High-Risk Prostate Cancer
2 Commerce Drive
Cranbury, NJ 08512